Evidence map›Paper›PMID 40985731›Full record

ArticleJournal of virology2025

Evolution of BA.2.86 to JN.1 reveals that functional changes in non-structural viral proteins are required for fitness of SARS-CoV-2.

Shuhei Tsujino, Masumi Tsuda, Naganori Nao, Kaho Okumura, Lei Wang, Yoshitaka Oda, Yume Mimura, Jingshu Li, Rina Hashimoto, Yasufumi Matsumura and 12 more

Abstract read
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Shuhei Tsujino *Department of Virology, Faculty of Medicine Sciences, Kyushu University, Fukuoka, Japan.ORCID 0009-0004-7542-3785
Masumi Tsuda *Department of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Naganori Nao *One Health Research Center, Hokkaido University, Sapporo, Japan.
Kaho OkumuraDivision of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Lei WangDepartment of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Yoshitaka OdaDepartment of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Yume MimuraDivision of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Jingshu LiDivision of Risk Analysis and Management, International Institute for Zoonosis Control, Hokkaido University, Sapporo, Japan.
Rina HashimotoCenter for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
Yasufumi MatsumuraDepartment of Clinical Laboratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0001-8595-8944
Rigel SuzukiDepartment of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Saori SuzukiDepartment of Virology, Faculty of Medicine Sciences, Kyushu University, Fukuoka, Japan.
Kumiko YoshimatsuInstitute for Genetic Medicine, Hokkaido University, Sapporo, Japan.ORCID 0000-0002-0062-2753
Miki NagaoDepartment of Clinical Laboratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0002-8886-6145
Jumpei ItoDivision of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Kazuo TakayamaCenter for iPS Cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.ORCID 0000-0002-1132-2457
Kei SatoDivision of Systems Virology, Department of Microbiology and Immunology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0003-4431-1380
Keita MatsunoOne Health Research Center, Hokkaido University, Sapporo, Japan.ORCID 0000-0002-4205-6526
Tomokazu TamuraDepartment of Virology, Faculty of Medicine Sciences, Kyushu University, Fukuoka, Japan.ORCID 0000-0003-1395-6610
Shinya TanakaDepartment of Cancer Pathology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.ORCID 0000-0001-6470-3301
Takasuke FukuharaDepartment of Virology, Faculty of Medicine Sciences, Kyushu University, Fukuoka, Japan.ORCID 0000-0001-5471-8331
Genotype to Phenotype Japan (G2P-Japan) Consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is still circulating among humans, leading to the continuous evolution. SARS-CoV-2 Omicron JN.1 evolved from a distinct SARS-CoV-2 lineage, BA.2.86, and spread rapidly worldwide. It is unclear why BA.2.86 did not become dominant and was quickly replaced by JN.1, which possesses one amino acid substitution in the spike protein (S:L455S) and two in the non-spike proteins NSP6 and ORF7b (NSP6:R252K and ORF7b:F19L) compared to BA.2.86. Here, we utilized recombinant viruses to elucidate the impact of these mutations on the virological characteristics of JN.1. We found that the mutation in the spike attenuated viral replication, while the non-spike mutations acted synergistically to enhance replication. This suggests that the mutations in the non-spike proteins compensate for the one in the spike, improving viral fitness, as the mutations in the spike contribute to further immune evasion. Our findings suggest that functional changes in both the spike and non-spike proteins are necessary for the evolution of SARS-CoV-2, enabling evasion of adaptive immunity within the human population while sustaining replication. IMPORTANCE: Because the spike protein is strongly associated with certain virological properties of SARS-CoV-2, such as immune evasion and infectivity, most previous studies on SARS-CoV-2 variants have focused on spike protein mutations. However, the non-spike proteins also contribute to infectivity, as observed throughout the evolution of Omicron subvariants. In this study, we demonstrate a "trade-off" strategy in SARS-CoV-2 Omicron JN.1 in which the reduced infectivity caused by spike mutation is compensated by non-spike mutations. Our results provide insight into the evolutionary scenario of the emerging virus in the human population.

Indexed as

COVID-19SARS-CoV-2Viral Nonstructural ProteinsAmino Acid SubstitutionAnimalsChlorocebus aethiopsEvolution, MolecularGenetic FitnessHumansMutationSpike Glycoprotein, CoronavirusVero CellsVirus ReplicationSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Viral Nonstructural ProteinsCOVID-19JN.1non-structural viral proteinNSP6ORF7bpathogenicityrecombinant virusSSARS-CoV-2

Identifiers

PMID40985731
PMCPMC12548449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.